This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with nivolumab plus brentuximab vedotin followed by brentuximab vedotin plus bendamustine…
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, comments on a retrospective analysis assessing the efficacy of combining venetoclax with intensive purine analog-based…
This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small…
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
When it comes to cancer prevention and early detection, knowledge can be power.
Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.
